Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00269828 · ClinicalTrials.gov registry record · Phase 3

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.

A Phase 3 study, sponsored by CTI BioPharma.

Terminated
Registry status
Phase 3
Development phase
600
Enrollment target

NCT00269828: Clinical Trial Phase 3 study, sponsored by CTI BioPharma.

NCT00269828 is a Phase 3 study that was terminated before completion, run by CTI BioPharma. The registered enrollment target is 600 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00269828, a Phase 3 study, was terminated before completion, sponsored by CTI BioPharma.

TERMINATED
Registry status
Phase 3
Development phase
600 participants
Enrollment target

Study Summary

This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle

Interventions

  • DRUG paclitaxel
  • DRUG paclitaxel poliglumex

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2005-12
Est. Completion 2006-12
Phase Phase 3
CTI BioPharma

28 total trials

Why NCT00269828 stopped before completion

NCT00269828 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower).

The record links to 0 conditions, and to 2 interventions - of which paclitaxel is the first listed.

NCT00269828 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00269828 about?

NCT00269828 is a clinical study titled "A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.". This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle

What is the current status of trial NCT00269828?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2005-12. Estimated completion is 2006-12.

What interventions are being tested in trial NCT00269828?

The interventions under investigation include: paclitaxel (DRUG), paclitaxel poliglumex (DRUG).

Who is sponsoring clinical trial NCT00269828?

This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00269828's enrollment target sits among peer trials

600 608th of 2000 higher than 1,363 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00269828, the US trial registry maintained by the National Library of Medicine. NCT00269828 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.